Absci CORP (ABSI) — SEC Filings

Overview

Absci CORP (ABSI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 24, 2026: Absci Corp (ABSI) is a clinical-stage biopharmaceutical company leveraging an AI-native platform for antibody therapeutics. The company has demonstrated capital efficiency, advancing its first two programs from AI design to IND (or foreign equivalent) in approximately two years with a total investme

Sentiment Summary

Across 29 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 24 neutral, 2 mixed. The dominant filing sentiment for Absci CORP is neutral.

Filing Type Overview

Absci CORP (ABSI) has filed 3 10-K, 6 10-Q, 10 8-K, 2 DEF 14A, 4 SC 13G, 3 SC 13G/A, 1 SC 13D/A with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (29)

• Absci's AI-Driven Drug Platform Accelerates Development, Targets $303.8M Market — 10-K · Mar 24, 2026 Risk: high
  Absci Corp (ABSI) is a clinical-stage biopharmaceutical company leveraging an AI-native platform for antibody therapeutics. The company has demonstrated capital
• Absci's Q3 Loss Widens Amidst Plummeting Partner Revenue — 10-Q · Nov 12, 2025 Risk: high
  Absci Corp (ABSI) reported a net loss of $28.706 million for the three months ended September 30, 2025, an increase from a net loss of $27.398 million in the sa
• Absci Corp Files 8-K for Material Definitive Agreement — 8-K · Nov 4, 2025 Risk: medium
  On October 31, 2025, Absci Corp entered into a material definitive agreement. The company, previously known as AbSci Corp, AbSci, Inc., and AbSci, LLC, is incor
• Absci's Revenue Jumps 37%, But Net Loss Widens to $28.5M — 10-Q · Aug 12, 2025 Risk: high
  Absci Corp (ABSI) reported a significant increase in revenue for the three months ended June 30, 2025, reaching $5.2 million, up from $3.8 million in the prior-
• Absci Corp Files 8-K: Material Agreement & Exhibits — 8-K · Jul 25, 2025 Risk: medium
  On July 25, 2025, Absci Corporation filed an 8-K report detailing a material definitive agreement. The filing also included other events and financial statement
• Absci Corp Elects New Directors David R. Walt and Jennifer L. Doudna — 8-K · Jul 8, 2025 Risk: medium
  Absci Corporation announced on July 7, 2025, a change in its board of directors. Specifically, the company elected two new directors, Dr. David R. Walt and Ms.
• Absci Corp Files 8-K on Shareholder Vote Matters — 8-K · Jun 12, 2025 Risk: low
  Absci Corp filed an 8-K on June 12, 2025, reporting on matters submitted to a vote of security holders on June 11, 2025. The filing details the company's corpor
• Absci Corp Q1 2025 10-Q Filed — 10-Q · May 13, 2025 Risk: low
  Absci Corp filed its 10-Q for the period ending March 31, 2025, reporting on its financial performance. The filing details changes in its equity accounts, inclu
• Absci Corp Files Definitive Proxy Statement — DEF 14A · Apr 28, 2025 Risk: low
  Absci Corporation filed its definitive proxy statement on April 28, 2025, for its annual meeting. The filing details information related to the company's govern
• Absci Corp Files 2024 10-K — 10-K · Mar 18, 2025 Risk: medium
  Absci Corp filed its 2024 10-K on March 18, 2025, reporting its fiscal year ending December 31, 2024. The company, headquartered in Vancouver, WA, operates in t
• Absci Corp Files 8-K Report — 8-K · Jan 15, 2025 Risk: low
  On January 15, 2025, Absci Corp filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or
• SC 13G Filing — SC 13G · Nov 14, 2024
• Absci Corp Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
  Absci Corp filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third quarter of 20
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G Filing — SC 13G · Nov 8, 2024
• SC 13G Filing — SC 13G · Oct 18, 2024
• Absci Corp Files 8-K: Corporate Details Updated — 8-K · Sep 4, 2024 Risk: low
  On September 4, 2024, Absci Corp filed an 8-K report. The filing indicates that the company is located at 18105 SE Mill Plain Blvd, Vancouver, WA 98683, and its
• Absci Corp Files Q2 2024 10-Q — 10-Q · Aug 14, 2024 Risk: medium
  Absci Corp filed its 10-Q for the period ending June 30, 2024. The company, based in Vancouver, WA, is involved in commercial physical & biological research. Ke
• Absci Corp Sets 2024 Annual Meeting Date — 8-K · Jun 14, 2024 Risk: low
  Absci Corp announced on June 12, 2024, that it has scheduled its 2024 Annual Meeting of Stockholders for July 17, 2024. The meeting will be held virtually, and
• Absci Corp Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 14, 2024 Risk: low
  Absci Corp (ABSI) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Absci Corp filed a 10-Q report for the period ending March 31, 2024. The filing
• Absci Corp Files Definitive Proxy Statement for 2024 Annual Meeting — DEF 14A · Apr 23, 2024 Risk: medium
  Absci Corp (ABSI) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Absci Corporation filed a Definitive Proxy Statement (DEF 14A) on April 23,
• Absci Corp Files 2023 Annual Report (10-K) — 10-K · Mar 21, 2024 Risk:
  Absci Corp (ABSI) filed a Annual Report (10-K) with the SEC on March 21, 2024. Absci Corp filed its 10-K report for the fiscal year ending December 31, 2023. Th
• Redmile Group Amends Absci Corp 13D Filing — SC 13D/A · Mar 5, 2024 Risk: medium
  Redmile Group, LLC, through its affiliate Redmile Biopharma Investments II, L.P., has filed an amendment (Amendment No. 1) to its Schedule 13D for Absci Corpora
• Absci Corp Files 8-K on Material Definitive Agreement — 8-K · Feb 28, 2024 Risk: medium
  Absci Corp filed an 8-K on February 28, 2024, reporting an event that occurred on February 27, 2024. The filing indicates an 'Entry into a Material Definitive A
• Absci Corp Files 8-K on Financials and Other Events — 8-K · Feb 27, 2024 Risk: low
  Absci Corp, a Delaware-incorporated company, filed a Current Report on Form 8-K with the SEC on February 27, 2024. The filing indicates that the company is repo
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G Filing — SC 13G · Feb 13, 2024
• FMR LLC & Abigail Johnson Maintain 14.914% Stake in Absci Corp — SC 13G/A · Feb 9, 2024 Risk: low
  FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in Absci Corp (ABSI). As of February 9, 2024,
• Absci Corp Files Routine 8-K on Jan 8, Confirming Registration Details — 8-K · Jan 8, 2024
  Absci Corp filed an 8-K on January 8, 2024, to report an 'Other Event' and 'Financial Statements and Exhibits.' This filing is a routine update, primarily confi

Risk Profile

Risk Assessment: Of ABSI's 21 recent filings, 3 were flagged as high-risk, 9 as medium-risk, and 9 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Absci CORP's most recent 10-K filing (Mar 24, 2026):

• Revenue: Not Disclosed
• Net Income: Not Disclosed
• EPS: Not Disclosed
• Debt-to-Equity: Not Disclosed
• Cash Position: Not Disclosed
• Operating Margin: Not Disclosed
• Total Assets: Not Disclosed
• Total Debt: Not Disclosed

Key Executives

• Vancouver, WA
• Delaware
• Dr. David R. Walt
• Ms. Jennifer L. Doudna
• Sean McClain
• Jeremy C. Green
• Abigail P. Johnson

Industry Context

Absci operates in the highly competitive biopharmaceutical industry, focusing on antibody therapeutics. The company differentiates itself through an AI-native platform that aims to accelerate drug discovery and reduce costs compared to traditional methods. Key trends include the increasing use of AI in drug development, the pursuit of novel targets for large unmet medical needs, and the ongoing pressure for capital efficiency in a capital-intensive sector.

Top Tags

financials (5) · Biotechnology (4) · 10-Q (4) · filing (3) · corporate-governance (3) · Absci Corp (3) · Net Loss (2) · 8-k (2) · AI Drug Discovery (2) · material-agreement (2)

Key Numbers

• Market Value of Non-Affiliate Equity: $303.8M — As of June 30, 2025, indicating current market perception.
• Time to IND (Absci): 2 years — Significantly faster than the industry average of 4-6 years, highlighting efficiency.
• Cost to IND (Absci): $15M — Substantially lower than the industry average of over $50 million, demonstrating capital efficiency.
• Shares Outstanding: 153,021,263 — As of March 6, 2026, relevant for per-share calculations and potential dilution.
• Industry Average Time to IND: 4-6 years — Provides a benchmark against Absci's accelerated timeline.
• Industry Average Cost to IND: $50M+ — Highlights Absci's cost-saving advantage.
• Net Loss (Q3 2025): $28.706M — Increased from $27.398M in Q3 2024
• Net Loss (9 Months 2025): $85.621M — Increased from $74.123M in 9 Months 2024
• Partner Program Revenue (Q3 2025): $378K — Decreased 77.8% from $1.701M in Q3 2024
• Partner Program Revenue (9 Months 2025): $2.150M — Decreased 44.4% from $3.869M in 9 Months 2024
• Cash and Cash Equivalents (Sept 30, 2025): $9.476M — Decreased from $41.213M at Dec 31, 2024
• Marketable Securities (Sept 30, 2025): $142.999M — Increased from $71.212M at Dec 31, 2024
• Research and Development Expenses (9 Months 2025): $56.071M — Increased from $45.482M in 9 Months 2024
• Common Shares Outstanding (Oct 31, 2025): 150,371,531 — Reflects significant dilution from prior periods
• Common Stock Issuances (9 Months 2025): $99.808M — Net proceeds from issuance of common shares

Forward-Looking Statements

• {"claim":"FMR LLC will maintain a significant ownership stake in Absci Corp, indicating continued long-term investment interest.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}

Related Companies

MRNA · BNTX · CRSP · EDIT

Frequently Asked Questions